ASND Ascendis Pharma A/S Ordinary Share
XNAS
242.99
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ASND
$242.99
—
Key stats
$242.99
- 52-Week Range
- $188.07 – $282.15
- YTD
- +13.92%
- IV Rank (30D)
- 59.03
- Straddle Price
- $26.25
- P/C Vol Ratio
- 0.11
- Market Cap
- $15.7B
- Open
- $239.38
- Day Range
- $236.87 – $243.87
- Volume
- 539,177
- Prev Close
- $238.90
Fair Value
MODEL: SHORT
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.15% |
| Beta vs SPY | 0.83 |
| Cost of Equity (CAPM) | 9.32% (VRP-adj) |
| WACC | 9.33% |
| Volatility Risk Premium | +14.1pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -38.8% |
| Book / Price | 0.2% |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -221.8% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $242.90 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $228.21 |
| Bollinger Width / SMA20 | 2.7% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $139B |
Peers used for multiples: ALNY, ARGX, GILD, GSK, ISRG, LLY, NTRA, UNH
60-Day Conviction
58%
20-Day Fair Value
≈ by Nov 20, 2026
$243.12
α +0.1%
rank 14%
conviction
4%
40-Day Fair Value
≈ by Dec 21, 2026
$244.35
α +0.6%
rank 14%
conviction
16%
60-Day Fair Value
≈ by Jan 19, 2027
$238.91
α -1.7%
rank 14%
conviction
58%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.5× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 28.6× · 5 peers |
| Peer P/B | $8.30 | 10% | median 19.6× · 6 peers |
| Peer P/S | $0.74 | 10% | median 10.2× · 6 peers |
| Market Anchor (SMA50) | $242.90 | 53% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $238.35 | 26% | 28 strikes · skew -0.14 |
As of 2026-10-22 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $15.7B
- Employees
- 1,189
- List Date
- 2026-04-20
- CIK
- 0001612042
- Next Earnings
- 2026-11-11
- EPS Forecast
- $1.14 (8 est.)
- Homepage
- https://www.ascendispharma.com
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | -9.27% | -10.39% | 2.78% | 1.88% | -5.32% | 6.01% | -2.39% |
| Feb | 3.74% | -7.32% | -10.05% | 4.33% | 25.17% | 4.43% | 3.38% |
| Mar | -17.54% | 7.84% | -5.29% | -0.85% | 2.59% | -5.52% | -3.13% |
| Apr | 11.17% | -21.30% | -3.94% | -8.91% | 12.55% | 0.50% | -1.66% |
| May | -7.51% | -7.18% | 0.27% | -4.19% | -2.76% | 1.44% | -3.32% |
| Jun | -1.48% | 9.58% | 1.47% | 0.79% | -1.76% | 21.89% | 5.08% |
| Jul | -12.13% | -7.63% | 2.28% | -0.36% | 0.87% | -8.69% | -4.28% |
| Aug | 30.24% | 6.59% | 6.99% | 1.41% | 11.34% | 8.05% | 10.77% |
| Sep | -3.82% | 15.91% | -4.71% | 10.86% | -0.18% | -12.46% | 0.93% |
| Oct | -6.56% | 15.67% | -2.00% | -16.22% | -1.23% | 6.90%* | -0.57% |
| Nov | -14.33% | 5.44% | 10.62% | 8.62% | 5.65% | -- | 3.20% |
| Dec | -5.01% | 0.31% | 21.05% | 3.12% | 1.13% | -- | 4.12% |
| Total | -34.20% | 0.09% | 17.10% | -2.55% | 54.65% | 20.00% | 9.18% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $228.82
SMA 50: $242.65
SMA 200: $236.99
Current: $242.99
EMA 12: $232.31
EMA 26: $233.98
MACD: -1.6765 | Signal: 2.6803
BEARISH
ADX (14): 28.90
TREND
+DI: 26.92
−DI: 18.65
Momentum Oscillators
RSI (14): 59.15
NEUTRAL
Stoch %K: 93.54
Stoch %D: 82.10
Williams %R: -3.61
Volume & Volatility
BB Upper: $238.33
BB Lower: $219.31
OVERBOUGHT
OBV: -1,886,145
Vol SMA 20: 746,145
Vol ROC: -41.70%
ATR: $7.11
True Range: $7.00
HV 20: 24.8%
HV 30: 43.9%
HV 60: 38.0%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-22T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: ASND CURRENT PRICE: $230.83
Executive Summary
- Overall Assessment: NEUTRAL (Confidence Level: 6/10)
- Key Drivers: Recent FDA approvals, strong fundamental performance
- Primary Risks: Limited institutional interest, high beta in recent past
- Investment Thesis: ASND has potential for long-term growth driven by its robust fundamentals and recent regulatory successes.
- Recent News Sentiment Impact: Positive news headlines have contributed to the stock's strength.
Technical Analysis
- Trend Direction: Medium-term uptrend (1-3 months)
- Support/Resistance Levels:
- Lower Bollinger Band: $200.58
- Middle Bollinger Band: $224.58
- Upper Bollinger Band: $248.57
- Momentum Signals:
- RSI (14): 54.44 (neutral)
- MACD: -1.93 / Signal: 1.91 / Histogram: -3.84 (bearish)
- Stochastic %K: 80.12
- Williams %R: -18.58
- Volume Analysis: Volume SMA 20: 618132.85, On-Balance Volume (OBV): 1794741.06
News & Sentiment Analysis
- Recent Headlines Summary: Recent FDA approvals, business updates, and product launches have contributed to a positive news sentiment.
- Sentiment Assessment: Positive
- Catalyst Identification: Upcoming earnings date and potential further regulatory approvals.
Risk & Volatility Assessment
- Beta Interpretation: Low risk relative to market (beta: 0.33)
- Volatility Regime: Current volatility is low compared to historical levels.
- Options Market Signals: IV rank: 23.1% (Low), current IV: 59.8%, expected move: $21.45
Market Context & Positioning
- Sector Performance: Strong performance relative to the Biotechnology sector.
- Institutional Activity: Limited institutional interest, with a put/call volume ratio of 2.66.
- Correlation Analysis: Stock moves less than market (R-squared: 0.11).
- Relative Valuation: Position within trading range.
Key Levels & Action Items
- Critical Price Levels: Support at $224.58 and resistance at $248.57
- Breakout/Breakdown Levels: Break above $248.57 for potential further upside or break below $200.58 for potential bearish continuation.
- Time-Sensitive Catalysts: Upcoming earnings date, FDA approvals, and product launches.
Risk Management:
- Stop-loss levels: $220.83
- Position sizing considerations: Start with a conservative position size due to limited institutional interest and high beta in the past.
This analysis provides a comprehensive view of ASND's current market conditions, highlighting both bullish and bearish cases. The technical indicators suggest a medium-term uptrend, while news sentiment remains positive. However, the options market signals a relatively low volatility environment, which could impact the stock's potential for significant moves.
Generated
News
All ASND news →
ASND Options Activity & IV Rank
ASND IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 47.1%
7-DTE IV: —
Expected Move: $26.25
7-DTE Move: $26.25
Days to Exp: 29 (2026-11-20)
Options Flow
Call Volume: 354
Put Volume: 38
P/C Volume: 0.107
BULLISH
Call OI: 1,732
Put OI: 299
P/C OI: 0.173
Total OI: 2,031
ATM Options Pricing
ATM Call: $15.15
ATM Put: $11.10
Call %: 6.2%
Put %: 4.6%
Chain Summary
Chain Volume: 2,289
Chain OI: 9,629
Last Updated: 10/22/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 54th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
54%
vs own history
GEX tilt
+0.22
OI-weighted, today
Vanna tilt
+0.32
δ-sensitivity to IV
Charm tilt
-0.14
δ-decay vs time
Vanna tilt +0.32: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 23 ATM contracts, 5k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
20%
+1.6
pts
EXTREME
ATM 47.7% / Wing 49.3%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)59.0MediumOct 22
Straddle Price (30 DTE)$26.25Oct 22
Beta Analysis
Risk Metrics
Beta: 0.2739
Alpha: 21.81%
Correlation: 0.0897
R-Squared: 0.8%
Stock Volatility: 38.9%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ASND
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $71.1M | #465 of 3716 | +41.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $36.8M | #834 of 6285 | new | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $31.9M | #505 of 3138 | +2.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $50K | #3369 of 4729 | +276.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ASND Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 615,851,090 (as of 2019-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
17 filers$183.41M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $46.89M | 25.56% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $30.43M | 16.59% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $18.64M | 10.16% | 2026-06-30 |
| 4 | Caption Management, LLC | $16.62M | 9.06% | 2026-06-30 |
| 5 | Millennium Management LLC Custodian | $16.19M | 8.83% | 2026-06-30 |
| 6 | IMC-Chicago, LLC Custodian | $15.39M | 8.39% | 2026-06-30 |
| 7 | Walleye Trading LLC | $9.92M | 5.41% | 2026-06-30 |
| 8 | Q Global Advisors, LLC | $9.38M | 5.11% | 2026-06-30 |
| 9 | D. E. Shaw & Co., Inc. Custodian | $8.38M | 4.57% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $4.08M | 2.22% | 2026-06-30 |
| 11 | DLD Asset Management, LP | $2.80M | 1.53% | 2026-06-30 |
| 12 | Simplex Trading, LLC Custodian | $2.08M | 1.13% | 2026-06-30 |
| 13 | SIG BROKERAGE, LP | $1.33M | 0.73% | 2026-06-30 |
| 14 | Walleye Capital LLC | $453.42K | 0.25% | 2026-06-30 |
| 15 | Two Sigma Investments, LP Custodian | $373.41K | 0.20% | 2026-06-30 |
| 16 | STG SECURITIES, LLC | $240.05K | 0.13% | 2026-06-30 |
| 17 | TUDOR INVESTMENT CORP ET AL | $213.38K | 0.12% | 2026-06-30 |
10 filers$62.63M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $24.83M | 39.65% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $13.20M | 21.08% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $7.01M | 11.20% | 2026-06-30 |
| 4 | TUDOR INVESTMENT CORP ET AL | $5.33M | 8.52% | 2026-06-30 |
| 5 | Walleye Trading LLC | $3.57M | 5.71% | 2026-06-30 |
| 6 | GROUP ONE TRADING LLC Custodian | $2.83M | 4.51% | 2026-06-30 |
| 7 | IMC-Chicago, LLC Custodian | $2.83M | 4.51% | 2026-06-30 |
| 8 | Simplex Trading, LLC Custodian | $2.45M | 3.92% | 2026-06-30 |
| 9 | Millennium Management LLC Custodian | $346.74K | 0.55% | 2026-06-30 |
| 10 | Walleye Capital LLC | $213.38K | 0.34% | 2026-06-30 |
ASND Insider Trading (Form 4)
Latest: 2026-09-28Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-28 | Jean Jacques Bienaime | Director | Mixed | — | — | EDGAR | |
| 2026-09-09 | Mads Bodenhoff | SVP & PAO | Mixed | — | $190.09 | -$480.6K | EDGAR |
| 2026-09-03 | Lars Holtug | Director | Sell (S) | −236 | $264.13 | -$62.3K | EDGAR |
| 2026-08-18 | Jean Jacques Bienaime | Director | Buy (P) | +2,000 | $246.33 | $492.7K | EDGAR |
| 2026-06-02 | Scott Thomas Smith | EVP & Chief Financial Officer | Buy (P) | +100 | $219.00 | $21.9K | EDGAR |
| 2026-06-01 | Scott Thomas Smith | EVP & Chief Financial Officer | Buy (P) | +250 | $223.32 | $55.8K | EDGAR |
| 2026-06-01 | Jean Jacques Bienaime | Director | Buy (P) | +500 | $223.12 | $111.6K | EDGAR |
| 2026-05-27 | Jean Jacques Bienaime | Director | Buy (P) | +400 | $237.80 | $95.1K | EDGAR |
| 2026-05-12 | Flemming Steen Jensen | See Remarks | Sell (S) | −19,460 | $238.49 | -$4.64M | EDGAR |
| 2019-09-03 | Adrian Rawcliffe | CEO and CFO | Grant (A) | +769,320 opt | — | EDGAR | |
| 2019-08-07 | Rafael Amado | President, R&D | Sell (S) | −11,043 | $2.06 | -$22.7K | EDGAR |
| 2019-08-05 | John Lunger | Chief Patient Supply Officer | Grant (A) | +1,027,068 opt | — | EDGAR | |
| 2019-07-03 | Barbara Gayle Duncan | Director | Grant (A) | +124,000 opt | — | EDGAR | |
| 2019-07-03 | Ali Behbahani | Director | Grant (A) | +234,407 opt | — | EDGAR | |
| 2019-07-03 | Lawrence M Alleva | Director | Grant (A) | +271,209 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ASND Insider Holdings
3 insiders · @ $242.99
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Scott Thomas Smith | EVP & Chief Financial Officer | 4,367 | $1.06M | $77.7K | 2 | 2026-06-02 |
| 2 | Lars Holtug | Director | 4,000 | $972.0K | -$62.3K | 1 | 2026-09-03 |
| 3 | Jean Jacques Bienaime | Director | 2,000 | $486.0K | $699.3K | 4 | 2026-09-28 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ASND Board & Officers
As of SEC filings through Sep 28, 2026Directors 7
- Albert Cha · since Mar 18, 2026
- Jan Moller Mikkelsen · since Mar 18, 2026
- Lars Holtug · since Mar 18, 2026
- Lisa Morrison · since Mar 18, 2026
- Siham Imani · since Mar 18, 2026
- William Fairey · since Mar 18, 2026
- Jean Jacques Bienaime · since Mar 23, 2026
Officers 8
- Jay Donovan Wu · EVP & President US Market · since Mar 18, 2026
- Scott Thomas Smith · EVP & Chief Financial Officer · since Mar 18, 2026
- Aimee Shu · EVP & Chief Medical Officer · since Mar 18, 2026
- Anni Lotte Kirstine Sonderbjerg Pedersen · EVP & Chief Admin Officer · since Mar 18, 2026
- Michael Wolff Jensen · EVP, Chief Legal Officer · since Mar 18, 2026
- Flemming Steen Jensen · EVP & Product Supply and Quality · since Mar 18, 2026
- Kennett Sprogoe · EVP & Head of Research & Product Development · since Mar 18, 2026
- Mads Bodenhoff · SVP & Pao · since Mar 18, 2026
Changes in the last 10 years (15)
| Mar 23, 2026 | Jean Jacques Bienaime became a director |
| Mar 18, 2026 | William Fairey became a director |
| Mar 18, 2026 | Siham Imani became a director |
| Mar 18, 2026 | Scott Thomas Smith became EVP & Chief Financial Officer |
| Mar 18, 2026 | Michael Wolff Jensen became EVP, Chief Legal Officer |
| Mar 18, 2026 | Mads Bodenhoff became SVP & Pao |
| Mar 18, 2026 | Lisa Morrison became a director |
| Mar 18, 2026 | Lars Holtug became a director |
| Mar 18, 2026 | Kennett Sprogoe became EVP & Head of Research & Product Development |
| Mar 18, 2026 | Jay Donovan Wu became EVP & President US Market |
| Mar 18, 2026 | Jan Moller Mikkelsen became a director |
| Mar 18, 2026 | Flemming Steen Jensen became EVP & Product Supply and Quality |
| Mar 18, 2026 | Anni Lotte Kirstine Sonderbjerg Pedersen became EVP & Chief Admin Officer |
| Mar 18, 2026 | Albert Cha became a director |
| Mar 18, 2026 | Aimee Shu became EVP & Chief Medical Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ASND Proposed Insider Sales (Form 144)
Latest: 2026-09-08
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $811K notice value
· 1 unique filer
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Bodenhoff Mads (1, $811K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | Officer | 3,000 | $810.6K | 2026-09-08 | Merrill Lynch | — | EDGAR |
| 2026-05-11 | JENSEN FLEMMING STEEN | Officer, EXECUTIVE VP HEAD OF PRODUCT SUPPLY AND QUALITY | 19,460 | $4.64M | 2026-05-11 | CITIGROUP GLOBAL MARKETS | — | EDGAR |
| 2026-03-09 | SINGEL STINA | Officer | 3,782 | $907.7K | 2026-03-09 | Merrill Lynch | — | EDGAR |
| 2026-03-06 | Bodenhoff Mads | Officer | 10,000 | $2.38M | 2026-03-06 | Merrill Lynch | — | EDGAR |
| 2026-03-06 144/A | SMITH SCOTT THOMAS | Officer | 10,000 | $2.40M | 2026-03-05 | Merrill Lynch | — | EDGAR |
| 2026-03-05 | Jan Moller Mikkelsen | CEO, Officer | 94,000 | $22.69M | 2026-03-05 | J.P. Morgan Securities LLC | — | EDGAR |
| 2026-03-05 | Shu Aimee | Officer | 5,583 | $1.32M | 2026-03-05 | Merrill Lynch | — | EDGAR |
| 2026-03-04 | Shu Aimee | Officer, EXECUTIVE VICE PRESIDENT CHIEF MEDICAL OFFICER | 7,290 | $1.74M | 2026-03-04 | CITIGROUP GLOBAL MARKETS | — | EDGAR |
| 2026-03-04 | Morrison Lisa | Officer | 10,105 | $2.39M | 2026-03-04 | Merrill Lynch | — | EDGAR |
| 2026-03-02 | Fairey William | Director | 1,800 | $435.8K | 2026-03-02 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
46 ETFs hold ASND
25 shown · $508.73M total exposure · 0.10% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 1.01% | $110.8M | $11.0B | 2026-10-20 |
| 2 | TCAF T. Rowe Price Capital Appreciation Equity ETF | Nport | 1.26% | $93.4M | — | 2026-06-30 |
| 3 | IWP iShares Russell Mid-Cap Growth ETF | iShares (BlackRock) | 0.35% | $66.4M | $19.3B | 2026-10-20 |
| 4 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.09% | $52.2M | $57.3B | 2026-10-20 |
| 5 | IWF iShares Russell 1000 Growth ETF | iShares (BlackRock) | 0.04% | $44.2M | $126.1B | 2026-10-20 |
| 6 | VONG Vanguard Russell 1000 Growth ETF | Vanguard | 0.03% | $18.7M | — | 2026-09-30 |
| 7 | FXH First Trust Health Care AlphaDEX® Fund | First Trust | 1.32% | $15.1M | $1.1B | 2026-10-20 |
| 8 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.04% | $14.6M | $40.9B | 2026-10-20 |
| 9 | VT Vanguard Total World Stock ETF | Vanguard | 0.01% | $10.6M | — | 2026-09-30 |
| 10 | FDG American Century Focused Dynamic Growth ETF | Nport | 2.52% | $10.4M | — | 2026-05-31 |
| 11 | TMSL T. Rowe Price Small-Mid Cap ETF | Nport | 0.35% | $9.4M | — | 2026-06-30 |
| 12 | IWB iShares Russell 1000 ETF | iShares (BlackRock) | 0.02% | $8.6M | $49.2B | 2026-10-20 |
| 13 | QQQJ Invesco NASDAQ Next Gen 100 ETF | Invesco | 0.73% | $8.6M | — | 2026-10-20 |
| 14 | IYH iShares U.S. Healthcare ETF | iShares (BlackRock) | 0.19% | $8.3M | $4.5B | 2026-10-20 |
| 15 | SMMD iShares Russell 2500 ETF | iShares (BlackRock) | 0.18% | $7.2M | $4.1B | 2026-10-20 |
| 16 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.88% | $6.6M | — | 2026-05-31 |
| 17 | FFOG Franklin Focused Dynamic Growth ETF | Franklin | 1.03% | $3.8M | $376.0M | 2026-10-20 |
| 18 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.03% | $3.5M | $10.9B | 2026-10-20 |
| 19 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.02% | $3.5M | $20.6B | 2026-10-20 |
| 20 | ILDR First Trust Innovation Leaders ETF | First Trust | 0.95% | $3.3M | $345.6M | 2026-10-20 |
| 21 | IDHQ Invesco S&P International Developed Quality ETF | Nport | 0.24% | $2.3M | — | 2026-07-31 |
| 22 | VONE Vanguard Russell 1000 ETF | Vanguard | 0.02% | $2.1M | — | 2026-09-30 |
| 23 | BDVL iShares Disciplined Volatility Equity Active ETF | iShares (BlackRock) | 0.11% | $2.0M | $1.8B | 2026-10-20 |
| 24 | TCAL T. Rowe Price Capital Appreciation Premium Income ETF | Nport | 0.56% | $1.5M | — | 2026-06-30 |
| 25 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.08% | $1.5M | — | 2026-10-20 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.16
TTM Revenue
$42.43M
TTM Net Income
$-99.43M
TTM Op. Cash Flow
$-92.12M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '19 | 2019-06-30 | $157.00K | $-41.09M | $-0.07 | $-34.17M |
| Q1 '19 | 2019-03-31 | — | $-27.41M | $-0.04 | $-36.20M |
| Q4 '18 | 2018-12-31 | $1.48M | $-36.17M | $-0.06 | $-31.68M |
| Q3 '18 | 2018-09-30 | $40.79M | $5.24M | $0.01 | $9.94M |
| Q2 '18 | 2018-06-30 | $9.04M | $-43.84M | $-0.08 | $-35.36M |
| Q1 '18 | 2018-03-31 | $8.20M | $-21.08M | $-0.04 | $-47.28M |
| Q4 '17 | 2017-12-31 | $4.27M | $-27.26M | $-0.05 | $-21.36M |
| Q3 '17 | 2017-09-30 | $27.18M | $-878.00K | — | $13.49M |
| Q2 '17 | 2017-06-30 | $3.52M | $-20.21M | $-0.04 | $-18.01M |
| Q1 '17 | 2017-03-31 | $2.86M | $-21.78M | $-0.05 | $-28.44M |
| Q4 '16 | 2016-12-31 | $8.54M | $-15.41M | $-0.04 | $2.37M |
| Q3 '16 | 2016-09-30 | $2.42M | $-18.49M | $-0.04 | $-15.37M |
Q2 2019 • period ending 2019-06-30 • filed 2020-08-06
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
800.28
P/S
3527.05
EV/EBITDA
—
EV/Sales
3526.23
ROE
-53.2%
ROA
-41.5%
Div Yield
—
FCF Yield
-0.06%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$149.65B
as of 2026-10-22
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
3.48M
SI % of Float
6.73%
Days to Cover
3.72
Short Vol Ratio
81.1%
Free Float
51.74M
Float %
83.5%
Short interest 2026-09-30 • Short volume 2026-10-22 • Float 2026-08-14